Article

Daily Medication Pearl: Vosoritide (Voxzogo) for Achondroplasia

Vosoritide is indicated to increase linear growth in pediatric patients with achondroplasia.

Medication Pearl of the Day: Vosoritide (Voxzogo)

Indication: Vosoritide is a C-type natriuretic peptide (CNP) analog indicated to increase linear growth in pediatric patients with achondroplasia who are 5 years of age and older with open epiphyses.

Insight:

  • Dosing: Recommended dosage is based on patient’s weight. Administer subcutaneously once daily.
  • Dosage forms: For injection 0.4 mg, 0.56 mg, or 1.2 mg lyophilized powder in a single-dose vial for reconstitution.
  • Adverse events (AEs): Most common AEs (>10%) are injection site erythema, injection site swelling, vomiting, injection site urticaria, arthralgia, decreased blood pressure, and gastroenteritis.
  • Mechanism of action: Binding of vosoritide to natriuretic peptide receptor-B antagonizes FGFR3 downstream signaling by inhibiting the extracellular signal-regulated kinases 1 and 2 in the mitogen-activated protein kinase pathway at the level of rapidly accelerating fibrosarcoma serine/threonine protein kinase. As a result, vosoritide, like CNP, acts as a positive regulator of endochondral bone growth as it promotes chondrocyte proliferation and differentiation.
  • Manufacturer: Biomarin Pharma

Sources:

label (fda.gov)

voxzogo - Google Search

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Tired scared retiree man holding chest with anginal symptoms, pallor and diaphoresis at home. Suffering male with cardiac origin pain, prexcordial pressure, arrhythmia risk, urgent medical attention - Image credit: DimaBerlin | stock.adobe.com
Image credit: Sebastian Kaulitzki | stock.adobe.com
Menoapuse spelled with wooden blocks -- Image credit: loran4a | stock.adobe.com